Volume 96, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



In Lusaka, Zambia, where malaria prevalence is low, national guidelines continue to recommend that all pregnant women receive sulfadoxine–pyrimethamine (SP) for malaria prophylaxis monthly at every scheduled antenatal care visit after 16 weeks of gestation. Human immunodeficiency virus (HIV)–positive women should receive co-trimoxazole prophylaxis for HIV and not SP, but many still receive SP. We sought to determine whether increased dosage of SP is still associated with a reduced risk of low birth weight (LBW) in an area where malaria transmission is low. Our secondary objective was to determine whether any association between SP and LBW is modified by receipt of antiretroviral therapy (ART). We analyzed data routinely collected from a cohort of HIV-positive pregnant women with singleton births in Lusaka, Zambia, between February 2006 and December 2012. We used a log-Poisson model to estimate the risk of LBW by dosage of SP and to determine whether the association between SP and LBW varied by receipt of ART. Risk of LBW declined as the number of doses increased and appeared lowest among women who received three doses (adjusted risk ratio [ARR] = 0.78; 95% confidence interval [CI] = 0.64–0.95). In addition, women receiving combination ART had a higher risk of delivering an LBW infant compared with women receiving no treatment or prophylaxis (ARR = 1.18; 95% CI = 1.09–1.28), but this risk was attenuated among women who were receiving SP (risk ratio = 1.09; 95% CI = 0.99–1.21). SP was associated with a reduced risk of LBW in HIV-positive women, including those receiving ART, in a low malaria prevalence region.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Chi BH, Vwalika B, Killam WP, Wamalume C, Giganti MJ, Mbewe R, Stringer EM, Chintu NT, Putta NB, Liu KC, Chibwesha CJ, Rouse DJ, Stringer JS, , 2011. Implementation of the Zambia electronic perinatal record system for comprehensive prenatal and delivery care. Int J Gynaecol Obstet 113: 131136.[Crossref] [Google Scholar]
  2. Masaninga F, Chanda E, Chanda-Kapata P, Hamainza B, Masendu HT, Kamuliwo M, Kapelwa W, Chimumbwa J, Govere J, Otten M, Fall IS, Babaniyi O, , 2013. Review of the malaria epidemiology and trends in Zambia. Asian Pac J Trop Biomed 3: 8994.[Crossref] [Google Scholar]
  3. U.S. Global Malaria Coordinator and Zambian Ministry of Community Development, Mother and Child Health, 2015. Zambia Malaria Operational Plan FY 2015. Washington, DC: United States Agency for International Development. [Google Scholar]
  4. Mount AM, Mwapasa V, Elliott SR, Beeson JG, Tadesse E, Lema VM, Molyneux ME, Meshnick SR, Rogerson SJ, , 2004. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 363: 18601867.[Crossref] [Google Scholar]
  5. Mwapasa V, Rogerson SJ, Molyneux ME, Abrams ET, Kamwendo DD, Lema VM, Tadesse E, Chaluluka E, Wilson PE, Meshnick SR, , 2004. The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. AIDS 18: 10511059.[Crossref] [Google Scholar]
  6. Ayisi JG, van Eijk AM, ter Kuile FO, Kolczak MS, Otieno JA, Misore AO, Kager PA, Steketee RW, Nahlen BL, , 2003. The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya. AIDS 17: 585594.[Crossref] [Google Scholar]
  7. Nkhoma ET, Bowman NM, Kalilani-Phiri L, Mwapasa V, Rogerson SJ, Meshnick SR, , 2012. The effect of HIV infection on the risk, frequency, and intensity of Plasmodium falciparum parasitemia in primigravid and multigravid women in Malawi. Am J Trop Med Hyg 87: 10221027.[Crossref] [Google Scholar]
  8. Steketee RW, Wirima JJ, Bloland PB, Chilima B, Mermin JH, Chitsulo L, Breman JG, , 1996. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 55 (Suppl 1): 4249. [Google Scholar]
  9. ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, van Eijk AM, Rogerson SJ, Steketee RW, , 2004. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 71 (Suppl 2): 4154. [Google Scholar]
  10. WHO, 2004. Malaria and HIV Interactions and Their Implications for Public Health Policy. Geneva, Switzerland: WHO. [Google Scholar]
  11. WHO, 2013. WHO Policy Brief for the Implementation of Intermittent Preventive Treatment of Malaria in Pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP). Geneva, Switzerland: WHO. [Google Scholar]
  12. Ministry of Health, 2014. Guidelines for the Diagnosis and Treatment of Malaria in Zambia. Lusaka, Zambia: Zambian Ministry of Health. [Google Scholar]
  13. The Zambian Ministry of Health and Ministry of Community Development, Mother and Child Health, 2014. Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection. Lusaka, Zambia: The Ministry of Health and Ministry of Community Development, Mother and Child Health. [Google Scholar]
  14. Uneke CJ, Ogbonna A, , 2009. Malaria and HIV co-infection in pregnancy in sub-Saharan Africa: impact of treatment using antimalarial and antiretroviral agents. Trans R Soc Trop Med Hyg 103: 761767.[Crossref] [Google Scholar]
  15. Kapito-Tembo A, Meshnick SR, van Hensbroek MB, Phiri K, Fitzgerald M, Mwapasa V, , 2011. Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. J Infect Dis 203: 464472.[Crossref] [Google Scholar]
  16. McClure EM, Goldenberg RL, Dent AE, Meshnick SR, , 2013. A systematic review of the impact of malaria prevention in pregnancy on low birth weight and maternal anemia. Int J Gynaecol Obstet 121: 103109.[Crossref] [Google Scholar]
  17. Tutu EO, Browne E, Lawson B, , 2011. Effect of sulphadoxine-pyrimethamine on neonatal birth weight and perceptions on its impact on malaria in pregnancy in an intermittent preventive treatment programme setting in Offinso District, Ghana. Int Health 3: 206212.[Crossref] [Google Scholar]
  18. Eisele TP, Larsen DA, Anglewicz PA, Keating J, Yukich J, Bennett A, Hutchinson P, Steketee RW, , 2012. Malaria prevention in pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in Africa. Lancet Infect Dis 12: 942949.[Crossref] [Google Scholar]
  19. Mathanga DP, Uthman OA, Chinkhumba J, , 2011. Intermittent preventive treatment regimens for malaria in HIV-positive pregnant women. Cochrane Database Syst Rev 5: CD006689. [Google Scholar]
  20. Hamer DH, Mwanakasale V, Macleod WB, Chalwe V, Mukwamataba D, Champo D, Mwananyanda L, Chilengi R, Mubikayi L, Mulele CK, Mulenga M, Thea DM, Gill CJ, , 2007. Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. J Infect Dis 196: 15851594.[Crossref] [Google Scholar]
  21. WHO/UNICEF, 2004. Low Birthweight: Country, Regional and Global Estimates. New York, NY: World Health Organization and UNICEF. [Google Scholar]
  22. Greenland S, , 2004. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 160: 301305.[Crossref] [Google Scholar]
  23. Knol MJ, VanderWeele TJ, Groenwold RH, Klungel OH, Rovers MM, Grobbee DE, , 2011. Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol 26: 433438.[Crossref] [Google Scholar]
  24. White NJ, , 2005. Intermittent presumptive treatment for malaria. PLoS Med 2: e3.[Crossref] [Google Scholar]
  25. Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL, , 1995. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 333: 17321736.[Crossref] [Google Scholar]
  26. Gonzalez R, Desai M, Macete E, Ouma P, Kakolwa MA, Abdulla S, Aponte JJ, Bulo H, Kabanywanyi AM, Katana A, Maculuve S, Mayor A, Nhacolo A, Otieno K, Pahlavan G, Rupérez M, Sevene E, Slutsker L, Vala A, Williamsom J, Menéndez C, , 2014. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial. PLoS Med 11: e1001735.[Crossref] [Google Scholar]
  27. Short CE, Taylor GP, , 2014. Antiretroviral therapy and preterm birth in HIV-infected women. Expert Rev Anti Infect Ther 12: 293306.[Crossref] [Google Scholar]
  28. Fiore S, Newell ML, Trabattoni D, Thorne C, Gray L, Savasi V, Tibaldi C, Ferrazzi E, Clerici M, , 2006. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol 70: 143150.[Crossref] [Google Scholar]
  29. Li N, Sando MM, Spiegelman D, Hertzmark E, Liu E, Sando D, Machumi L, Chalamilla G, Fawzi W, , 2015. Antiretroviral therapy in relation to birth outcomes among HIV-infected women: a cohort study. J Infect Dis. 213: 10571064.[Crossref] [Google Scholar]
  30. Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, van Widenfelt E, Moffat C, Moyo S, Makhema J, Essex M, Shapiro RL, , 2011. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 204: 506514.[Crossref] [Google Scholar]
  31. Fowler MG, Qin M, Fiscus SA, Currier JS, Makanani B, Martinson F, Chipato T, Browning R, Shapiro D, Mofenson L, , 2015. PROMISE: Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission. Conference on Retroviruses and Opportunistic Infections (CROI). February 23–26, 2015, Seattle, WA. [Google Scholar]
  32. Mofenson LM, , 2015. Antiretroviral therapy and adverse pregnancy outcome: the elephant in the room? J Infect Dis 213: 10511054.[Crossref] [Google Scholar]
  33. Fiore S, Ferrazzi E, Newell ML, Trabattoni D, Clerici M, , 2007. Protease inhibitor-associated increased risk of preterm delivery is an immunological complication of therapy. J Infect Dis 195: 914916.[Crossref] [Google Scholar]
  34. Skinner-Adams TS, McCarthy JS, Gardiner DL, Andrews KT, , 2008. HIV and malaria co-infection: interactions and consequences of chemotherapy. Trends Parasitol 24: 264271.[Crossref] [Google Scholar]
  35. Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT, , 2004. Antiretrovirals as antimalarial agents. J Infect Dis 190: 19982000.[Crossref] [Google Scholar]
  36. Stringer EM, Vwalika B, Killam WP, Giganti MJ, Mbewe R, Chi BH, Chintu N, Rouse D, Goldenberg RL, Stringer JS, , 2011. Determinants of stillbirth in Zambia. Obstet Gynecol 117: 11511159.[Crossref] [Google Scholar]
  37. Chanda E, Baboo KS, Shinondo CJ, , 2012. Transmission attributes of periurban malaria in Lusaka, Zambia, precedent to the integrated vector management strategy: an entomological input. J Trop Med 2012: 873852. [Google Scholar]
  38. Bengtson AM, Westreich D, Musonda P, Pettifor A, Chibwesha C, Chi BH, Vwalika B, Pence BW, Stringer JS, Miller WC, , 2016. Multiple overimputation to address missing data and measurement error: application to HIV treatment during pregnancy and pregnancy outcomes. Epidemiology 27: 642650.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 11 Aug 2016
  • Accepted : 21 Sep 2016
  • Published online : 11 Jan 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error